Merck & Co., Inc. And Japan Tobacco Inc. Sign Licensing Agreement For Novel Osteoanabolic Drug Candidate To Treat Osteoporosis

Merck & Co., Inc. and Japan Tobacco Inc. (JT) (TSE: 2914) today announced a worldwide licensing agreement to develop and commercialize JTT-305, an investigational oral osteoanabolic (bone growth stimulating) agent for the treatment of osteoporosis, a disease which reduces bone density and strength and results in an increased risk of bone fractures. Under the terms of the agreement, Merck gains worldwide rights, except for Japan, to develop and commercialize JTT-305.

More: continued here

Filed under: Bones on October 1st, 2008